A K Pau

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Impaired maraviroc and raltegravir clearance in a human immunodeficiency virus-infected patient with end-stage liver disease and renal impairment: a management dilemma
    Alice K Pau
    Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Pharmacotherapy 32:e1-6. 2012
  2. ncbi Recognition and management of significant drug interactions in HIV patients: challenges in using available data to guide therapy
    A K Pau
    Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Clin Pharmacol Ther 88:712-9. 2010
  3. ncbi Predictors for hematopoietic growth factors use in HIV/HCV-coinfected patients treated with peginterferon alfa 2b and ribavirin
    Alice K Pau
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    AIDS Patient Care STDS 20:612-9. 2006
  4. ncbi Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir
    Roshan Ramanathan
    Clinical Parasitology Unit and Helminth Immunology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Clin Infect Dis 47:e97-9. 2008
  5. ncbi A potentially significant interaction between efavirenz and phenytoin: a case report and review of the literature
    Sarah M Robertson
    Clinical Pharmacokinetics Research Laboratory, Clinical Center Pharmacy Department, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Clin Infect Dis 41:e15-8. 2005
  6. ncbi Therapeutic use of interleukin-2 in HIV-infected patients
    Alice K Pau
    National Institutes of Health, Clinical Center Pharmacy Department, Building 10, Room 1N257, Bethesda, Maryland 20892, USA
    Curr Opin Pharmacol 2:433-9. 2002
  7. ncbi Drug interactions in the management of HIV infection
    Sarah M Robertson
    National Institutes of Health, Clinical Pharmacokinetics Research Laboratory, Clinical Center Pharmacy Department, Bethesda, Maryland 20892, USA
    Expert Opin Pharmacother 6:233-53. 2005
  8. ncbi Instability of lopinavir/ritonavir capsules at ambient temperatures in sub-Saharan Africa: relevance to WHO antiretroviral guidelines
    Alice K Pau
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    AIDS 19:1233-4. 2005
  9. ncbi Guidelines for using antiretroviral agents among HIV-infected adults and adolescents
    Mark Dybul
    National Institutes of Health, Bethesda, Maryland, USA
    Ann Intern Med 137:381-433. 2002
  10. ncbi Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV
    Mark Dybul
    National Institutes of Health, Bethesda, Maryland, USA
    MMWR Recomm Rep 51:1-55. 2002

Detail Information

Publications11

  1. ncbi Impaired maraviroc and raltegravir clearance in a human immunodeficiency virus-infected patient with end-stage liver disease and renal impairment: a management dilemma
    Alice K Pau
    Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Pharmacotherapy 32:e1-6. 2012
    ..Until more data are available, therapeutic drug monitoring remains the only evidence-based approach to optimize dosage selection of these drugs in this patient population...
  2. ncbi Recognition and management of significant drug interactions in HIV patients: challenges in using available data to guide therapy
    A K Pau
    Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Clin Pharmacol Ther 88:712-9. 2010
    ..1,2) This article addresses some key challenges that prescribers face when using available drug interaction-data resources in making day-to-day clinical decisions...
  3. ncbi Predictors for hematopoietic growth factors use in HIV/HCV-coinfected patients treated with peginterferon alfa 2b and ribavirin
    Alice K Pau
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    AIDS Patient Care STDS 20:612-9. 2006
    ..Larger clinical trials will be needed to address the cost effectiveness of supplemental growth factor use in the HIV/HCV-coinfected patients...
  4. ncbi Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir
    Roshan Ramanathan
    Clinical Parasitology Unit and Helminth Immunology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Clin Infect Dis 47:e97-9. 2008
    ..This case highlights the potential of ritonavir interactions even with local injections of a corticosteroid...
  5. ncbi A potentially significant interaction between efavirenz and phenytoin: a case report and review of the literature
    Sarah M Robertson
    Clinical Pharmacokinetics Research Laboratory, Clinical Center Pharmacy Department, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Clin Infect Dis 41:e15-8. 2005
    ..Therapeutic drug monitoring was used in this case to ensure adequate efavirenz exposure...
  6. ncbi Therapeutic use of interleukin-2 in HIV-infected patients
    Alice K Pau
    National Institutes of Health, Clinical Center Pharmacy Department, Building 10, Room 1N257, Bethesda, Maryland 20892, USA
    Curr Opin Pharmacol 2:433-9. 2002
    ..Immune-based therapy with interleukin-2 when used as adjunctive therapy to antiretroviral therapy may further improve immune responses, as demonstrated by an increase in CD4(+) T-lymphocyte counts in recent clinical trials...
  7. ncbi Drug interactions in the management of HIV infection
    Sarah M Robertson
    National Institutes of Health, Clinical Pharmacokinetics Research Laboratory, Clinical Center Pharmacy Department, Bethesda, Maryland 20892, USA
    Expert Opin Pharmacother 6:233-53. 2005
    ..The mechanisms and significance of interactions involving antiretrovirals, drugs used for opportunistic infections, and other medications commonly used in HIV patients will be reviewed...
  8. ncbi Instability of lopinavir/ritonavir capsules at ambient temperatures in sub-Saharan Africa: relevance to WHO antiretroviral guidelines
    Alice K Pau
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    AIDS 19:1233-4. 2005
    ..Although maintaining chemical stability for 4 weeks at 35 degrees C, at 45 degrees C the capsules clumped after 7 days, supporting a need for more temperature-stable formulations for hotter climates...
  9. ncbi Guidelines for using antiretroviral agents among HIV-infected adults and adolescents
    Mark Dybul
    National Institutes of Health, Bethesda, Maryland, USA
    Ann Intern Med 137:381-433. 2002
    ..Because concepts regarding HIV management are evolving rapidly, readers should check regularly for additional information and updates at the HIV/AIDS Treatment Information Service website ( http://www.hivatis.org )...
  10. ncbi Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV
    Mark Dybul
    National Institutes of Health, Bethesda, Maryland, USA
    MMWR Recomm Rep 51:1-55. 2002
    ..Because concepts regarding HIV management are evolving rapidly, readers should check regularly for additional information and updates at the HIV/AIDS Treatment Information Service website (http://www.hivatis.org)...
  11. ncbi Plasma pharmacokinetics of sulfadiazine administered twice daily versus four times daily are similar in human immunodeficiency virus-infected patients
    M Kelli Jordan
    Pharmacy Department, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Antimicrob Agents Chemother 48:635-7. 2004
    ..No differences in pharmacokinetic parameters were detected between the regimens. These data provide a pharmacokinetic rationale for BID dosing of sulfadiazine for the treatment and suppression of toxoplasmosis...